Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA

Open source

DOI: 10.1182/blood-2015-06-644336
Published: 2015 Dec 24
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2015-06-644336,
  title = {Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.},
  author = {Forero-Torres A and Holkova B and Goldschmidt J and Chen R and Olsen G and Boccia RV and Bordoni RE and Friedberg JW and Sharman JP and Palanca-Wessels MC and Wang Y and Yasenchak CA},
  year = {2015},
  journal = {Blood},
  doi = {10.1182/blood-2015-06-644336},
  url = {https://doi.org/10.1182/blood-2015-06-644336}
}

RIS

TY  - JOUR
TI  - Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
AU  - Forero-Torres A
AU  - Holkova B
AU  - Goldschmidt J
AU  - Chen R
AU  - Olsen G
AU  - Boccia RV
AU  - Bordoni RE
AU  - Friedberg JW
AU  - Sharman JP
AU  - Palanca-Wessels MC
AU  - Wang Y
AU  - Yasenchak CA
PY  - 2015
JO  - Blood
DO  - 10.1182/blood-2015-06-644336
UR  - https://doi.org/10.1182/blood-2015-06-644336
ER  -

APA

A, F., B, H., J, G., R, C., G, O., RV, B., RE, B., JW, F., JP, S., MC, P., Y, W., & CA, Y. (2015). Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.. Blood. https://doi.org/10.1182/blood-2015-06-644336

Source records

pubmed · retrieved 2026-09-27T07:51:42.522Z